Skip to content
OpenCapital
Get started

Standard BioTools Inc. LAB Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$19.6MBeat by $1.1M
EPS-$0.04Miss by $0.02
Revenue estimate$18.5M
EPS estimate-$0.03

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$20.8M
EPS estimate-$0.01

Versus estimates

Revenue

Q1 2026$21.1MBeat by $3.3MQ4 2025$23.8MBeat by $5.3M
Q3 2025$19.6MBeat by $1.1M
Q2 2025$21.8MMiss by $19.1MQ1 2025$40.8MBeat by $1.6MQ4 2024$46.7MBeat by $3.7M

Diluted EPS

Q1 2026-$0.02In lineQ4 2025$0.06Beat by $0.09
Q3 2025-$0.04Miss by $0.02
Q2 2025-$0.04In lineQ1 2025-$0.04In lineQ4 2024-$0.05Beat by $0.02

Ask the moment Standard BioTools Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Standard BioTools Inc. report Q3 2025 earnings?
Standard BioTools Inc. (LAB) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Standard BioTools Inc.'s Q3 2025 revenue and EPS?
Standard BioTools Inc. reported revenue of $19.6M and eps of $-0.04 for Q3 2025.
Did Standard BioTools Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $18.5M by $1.1M. EPS missed the consensus estimate of $-0.03 by $0.01.
How did Standard BioTools Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 56.5% from $45.0M a year earlier and eps grew 20.0% from $-0.05.
Where can I find Standard BioTools Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-264693) and the 10-Q periodic report (0001193125-25-264695) directly on SEC EDGAR. The filing index links above go to sec.gov.